312 related articles for article (PubMed ID: 24058649)
41. RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.
Lang JE; Ring A; Porras T; Kaur P; Forte VA; Mineyev N; Tripathy D; Press MF; Campo D
Ann Surg Oncol; 2018 Aug; 25(8):2261-2270. PubMed ID: 29868978
[TBL] [Abstract][Full Text] [Related]
42. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
43. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
44. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
45. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
46. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Pestrin M; Salvianti F; Galardi F; De Luca F; Turner N; Malorni L; Pazzagli M; Di Leo A; Pinzani P
Mol Oncol; 2015 Apr; 9(4):749-57. PubMed ID: 25539732
[TBL] [Abstract][Full Text] [Related]
47. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
[TBL] [Abstract][Full Text] [Related]
48. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.
Krishnamurthy S; Bischoff F; Ann Mayer J; Wong K; Pham T; Kuerer H; Lodhi A; Bhattacharyya A; Hall C; Lucci A
Cancer Med; 2013 Apr; 2(2):226-33. PubMed ID: 23634290
[TBL] [Abstract][Full Text] [Related]
49. Biomarkers characterization of circulating tumour cells in breast cancer patients.
Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
51. HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques.
Brouwer A; De Laere B; van Dam PJ; Peeters D; Van Haver J; Sluydts E; El Moussaoui A; Mendelaar P; Kraan J; Peeters M; Van Laere S; Dirix L
PLoS One; 2019; 14(9):e0220906. PubMed ID: 31483799
[TBL] [Abstract][Full Text] [Related]
52. Molecular biomarker analyses using circulating tumor cells.
Punnoose EA; Atwal SK; Spoerke JM; Savage H; Pandita A; Yeh RF; Pirzkall A; Fine BM; Amler LC; Chen DS; Lackner MR
PLoS One; 2010 Sep; 5(9):e12517. PubMed ID: 20838621
[TBL] [Abstract][Full Text] [Related]
53. Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer.
Singh A; Denu RA; Wolfe SK; Sperger JM; Schehr J; Witkowsky T; Esbona K; Chappell RJ; Weaver BA; Burkard ME; Lang JM
Mol Oncol; 2020 Aug; 14(8):1898-1909. PubMed ID: 32255253
[TBL] [Abstract][Full Text] [Related]
54. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
55. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li Z; Wu Y; Yates ME; Tasdemir N; Bahreini A; Chen J; Levine KM; Priedigkeit NM; Nasrazadani A; Ali S; Buluwela L; Arnesen S; Gertz J; Richer JK; Troness B; El-Ashry D; Zhang Q; Gerratana L; Zhang Y; Cristofanilli M; Montanez MA; Sundd P; Wallace CT; Watkins SC; Fumagalli C; Guerini-Rocco E; Zhu L; Tseng GC; Wagle N; Carroll JS; Jank P; Denkert C; Karsten MM; Blohmer JU; Park BH; Lucas PC; Atkinson JM; Lee AV; Oesterreich S
Cancer Res; 2022 Apr; 82(7):1321-1339. PubMed ID: 35078818
[TBL] [Abstract][Full Text] [Related]
56. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
57. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
[TBL] [Abstract][Full Text] [Related]
58. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
59. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.
Kwan TT; Bardia A; Spring LM; Giobbie-Hurder A; Kalinich M; Dubash T; Sundaresan T; Hong X; LiCausi JA; Ho U; Silva EJ; Wittner BS; Sequist LV; Kapur R; Miyamoto DT; Toner M; Haber DA; Maheswaran S
Cancer Discov; 2018 Oct; 8(10):1286-1299. PubMed ID: 30104333
[TBL] [Abstract][Full Text] [Related]
60. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.
Lang JE; Mosalpuria K; Cristofanilli M; Krishnamurthy S; Reuben J; Singh B; Bedrosian I; Meric-Bernstam F; Lucci A
Breast Cancer Res Treat; 2009 Feb; 113(3):501-7. PubMed ID: 18327638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
